…that can make a difference to
the quality of life of people
Intercedo is presently focussing on the development of medical products for the treatment of Parkinson’s disease through its principal ownership and involvement in Dizlin Pharmaceuticals AB. For more information, please refer to www.dizlin.se
The Intercedo group was founded more than 30 years ago. The group’s activities were for long centred around the international health & beauty industry with manufacturing plants and sales organisations in Sweden, Great Britain, and the Netherlands. The group has also been involved in the development and production of products for industrial automation. The Intercedo group products have been sold to more than 40 countries throughout the world. Providing financing to the group’s customers has always been a vital part of the group’s strategy and wholly owned financing companies have played an important role in supporting the sales of the group’s products on major markets.30
The Intercedo group has changed its strategy in recent years directing its activities towards research and development. The main interest has also gradually shifted to the medical field. Along with the strategic change the Intercedo group has divested its operations outside Sweden and the number of companies has been reduced from about 20 companies to a few research oriented Sweden-based enterprises.
Intercedo’s goal is to continue participating in partnerships and companies, which are involved in the development of products and methods directed towards improving people’s quality of life.
Dizlin Pharmaceuticals announced today that the European Patent Office (EPO) has issued a Decision to Grant a European patent pursuant to Article 97(1) EPC following examination of European patent application
In a pharmacokinetic cross-over study, 18 patients with Parkinson ́s disease were assessed for 16 hours with respect to blood levels of levodopa when administered with levodopa plus carbidopa subcutaneously
The Intercedo Group was appointed a Gazelle company in 2010. The award is issued by Scandinavia’s leading business magazine, Dagens Industri. The Gazelle – being a fast-running Antelope – symbolizes a fast-moving and progressive company.
Prästgårdsgatan 11 SE-598 36 Vimmerby Sweden
+46 708 77 88 99
About Us
Intercedo, which was founded more than 30 years ago, is involved in research & development aiming at developing products and concepts that makes a difference to people’s quality of life.
Links
Contact Us
Website by Weblab
Transientic Interactions AB, in which Intercedo is a principal owner, has launched a new method for pre-clinical development of medical drugs. The new method named WAC (Weak Affinity Chromatography) has been developed by Professor Sten Olsson at the Linné University at Kalmar, Sweden. The large Multinational Pharmaceutical Company, Astra Zeneca, and the world’s largest medical equipment manufacturer, Agilent, have both participated in the development of the method. WAC was launched at FBLD (Fragment-based Lead Discovery Conference) in San Francisco, USA in September 2012.
Fragment Screening is the latest technique used by the pharmaceutical industry for discovering new molecules that may be medical drug candidates. Large amounts of substances are scanned –it is easily 10 000 and up to 500 000 per screening. WAC is a new more efficient way of performing fragment screening than the traditional High Throughput Techniques: Increased efficiency is of utmost importance considering the large amount of substances being screened. In addition, WAC, gives more information e.g. the affinity (chemical bond) beween the molecules. A brittish participant at FBLD exclaimed: “WAC is the biggest news presented at this conference at it will make a difference in drug discovery from now on”.
The Intercedo Group was appointed a Gazelle company in 2010. The award is issued by Scandinavia’s leading business magazine, Dagens Industri. The Gazelle – being a fast-running Antelope – symbolizes a fast-moving and progressive company. A number of conditions needs to be fulfilled in order for a company to qualify for being a Gazelle company.